Trial Outcomes & Findings for ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab (NCT NCT03056040)

NCT ID: NCT03056040

Last Updated: 2025-03-12

Results Overview

Lactate dehydrogenase (LDH) is an indicator of intravascular hemolysis that occurs in participants with paroxysmal nocturnal hemoglobinuria. A decrease in LDH indicates reduction (improvement) in hemolysis. Baseline was defined as the average of all available on-study assessments prior to the first study drug infusion. The percent change in LDH was analyzed using a mixed-effect model for repeated measures (MMRM) with the fixed, categorical effects of treatment, study visit, and study visit by treatment group interaction, as well as the continuous, fixed covariate of baseline LDH and the stratification randomization indicator of packed red blood cells transfusion history (yes/no within 12 months prior to Day 1).

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 202 participants
• Primary outcome timeframe: Baseline, Day 183
• Results posted on: 2025-03-12

Participant Flow

Participants were stratified into 1 of 2 groups based on their transfusion history. Stratified participants were randomly assigned in a 1:1 ratio to receive ravulizumab or eculizumab.

Participant milestones

Measure	Ravulizumab/Ravulizumab On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Eculizumab/Ravulizumab Participants received 900 mg of eculizumab every 2 weeks (q2w) for 26 weeks. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.
Primary Evaluation Period STARTED	98	99
Primary Evaluation Period Received at Least 1 Dose of Study Drug	97	98
Primary Evaluation Period Participants in the Full Analysis Set (FAS)	97	98
Primary Evaluation Period COMPLETED	96	95
Primary Evaluation Period NOT COMPLETED	2	4
Extension Period STARTED	96	95
Extension Period COMPLETED	92	88
Extension Period NOT COMPLETED	4	7

Reasons for withdrawal

Measure	Ravulizumab/Ravulizumab On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Eculizumab/Ravulizumab Participants received 900 mg of eculizumab every 2 weeks (q2w) for 26 weeks. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.
Primary Evaluation Period Withdrawal by Subject	1	1
Primary Evaluation Period Lack of Efficacy	0	1
Primary Evaluation Period Pregnancy	0	1
Primary Evaluation Period Randomized, not treated	1	1
Extension Period Physician Decision	3	3
Extension Period Lost to Follow-up	0	1
Extension Period Death	0	3
Extension Period Withdrawal by Subject	1	0

Baseline Characteristics

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Baseline characteristics by cohort

Measure	Ravulizumab/Ravulizumab n=97 Participants On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Eculizumab/Ravulizumab n=98 Participants Participants received 900 mg of eculizumab q2w for 26 weeks. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Total n=195 Participants Total of all reporting groups
Age, Continuous	46.6 years STANDARD_DEVIATION 14.41 • n=5 Participants	48.8 years STANDARD_DEVIATION 13.97 • n=7 Participants	47.7 years STANDARD_DEVIATION 14.19 • n=5 Participants
Sex: Female, Male Female	47 Participants n=5 Participants	50 Participants n=7 Participants	97 Participants n=5 Participants
Sex: Female, Male Male	50 Participants n=5 Participants	48 Participants n=7 Participants	98 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	3 Participants n=5 Participants	4 Participants n=7 Participants	7 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	76 Participants n=5 Participants	77 Participants n=7 Participants	153 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	18 Participants n=5 Participants	17 Participants n=7 Participants	35 Participants n=5 Participants
Race/Ethnicity, Customized White	50 participants n=5 Participants	61 participants n=7 Participants	111 participants n=5 Participants
Race/Ethnicity, Customized Asian	23 participants n=5 Participants	19 participants n=7 Participants	42 participants n=5 Participants
Race/Ethnicity, Customized Not Reported	13 participants n=5 Participants	13 participants n=7 Participants	26 participants n=5 Participants
Race/Ethnicity, Customized Black or African American	5 participants n=5 Participants	3 participants n=7 Participants	8 participants n=5 Participants
Race/Ethnicity, Customized Unknown	3 participants n=5 Participants	1 participants n=7 Participants	4 participants n=5 Participants
Race/Ethnicity, Customized Other	2 participants n=5 Participants	1 participants n=7 Participants	3 participants n=5 Participants
Race/Ethnicity, Customized Multiple	1 participants n=5 Participants	0 participants n=7 Participants	1 participants n=5 Participants

PRIMARY outcome

Timeframe: Baseline, Day 183

Population: Full Analysis Set: All participants who received at least 1 dose of randomized treatment (ravulizumab or eculizumab).

Lactate dehydrogenase (LDH) is an indicator of intravascular hemolysis that occurs in participants with paroxysmal nocturnal hemoglobinuria. A decrease in LDH indicates reduction (improvement) in hemolysis. Baseline was defined as the average of all available on-study assessments prior to the first study drug infusion. The percent change in LDH was analyzed using a mixed-effect model for repeated measures (MMRM) with the fixed, categorical effects of treatment, study visit, and study visit by treatment group interaction, as well as the continuous, fixed covariate of baseline LDH and the stratification randomization indicator of packed red blood cells transfusion history (yes/no within 12 months prior to Day 1).

Outcome measures

Measure	Ravulizumab/Ravulizumab n=97 Participants On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Eculizumab/Ravulizumab n=98 Participants Participants who were randomized to the eculizumab group in the Primary Evaluation Period received a weight-based loading dose of ravulizumab on Day 183 followed by weight-based maintenance doses of ravulizumab 2 weeks later and q8w until the end of study (up to 4 years).
Percent Change In Lactate Dehydrogenase Levels From Baseline To Day 183	-0.82 percent change Interval -7.75 to 6.11	8.39 percent change Interval 1.47 to 15.32

SECONDARY outcome

Timeframe: Baseline through Day 183

Population: Full Analysis Set: All participants who received at least 1 dose of randomized treatment (ravulizumab or eculizumab).

Breakthrough hemolysis (BTH) was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia [hemoglobin <10 grams (g)/deciliter (dL)], major adverse vascular event [including thrombosis], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 times the upper limit of normal (ULN).

Outcome measures

Measure	Ravulizumab/Ravulizumab n=97 Participants On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Eculizumab/Ravulizumab n=98 Participants Participants who were randomized to the eculizumab group in the Primary Evaluation Period received a weight-based loading dose of ravulizumab on Day 183 followed by weight-based maintenance doses of ravulizumab 2 weeks later and q8w until the end of study (up to 4 years).
Number Of Participants With Breakthrough Hemolysis Through Day 183	0 number of participants Interval 0.0 to 3.73	5 number of participants Interval 1.68 to 11.51

SECONDARY outcome

Timeframe: Baseline, Day 183

Population: Full Analysis Set: All participants who received at least 1 dose of randomized treatment (ravulizumab or eculizumab).

FACIT-Fatigue score ranges from 0 to 52, with a higher score indicating less fatigue. Baseline was defined as the last non-missing assessment value prior to first study drug dose. Change in FACIT-Fatigue score from Baseline to Day 183 was analyzed using an MMRM with the fixed, categorical effects of treatment, the stratification randomization indicator of packed red blood cells transfusion history (yes/no within 12 months prior to Day 1), study visit, and study visit by treatment group interaction, as well as the continuous fixed covariate of Baseline FACIT-Fatigue score.

Outcome measures

Measure	Ravulizumab/Ravulizumab n=97 Participants On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Eculizumab/Ravulizumab n=98 Participants Participants who were randomized to the eculizumab group in the Primary Evaluation Period received a weight-based loading dose of ravulizumab on Day 183 followed by weight-based maintenance doses of ravulizumab 2 weeks later and q8w until the end of study (up to 4 years).
Change From Baseline To Day 183 In Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Scores	2.01 units on a scale Interval 0.64 to 3.39	0.54 units on a scale Interval -0.84 to 1.93

SECONDARY outcome

Timeframe: Baseline through Day 183

Population: Full Analysis Set: All participants who received at least 1 dose of randomized treatment (ravulizumab or eculizumab).

Transfusion avoidance was defined as the percentage of participants who remained transfusion free and did not require a transfusion per protocol-specified guidelines (hemoglobin value of ≤9 g/dL with signs or symptoms of sufficient severity to warrant a transfusion, or a hemoglobin value of ≤7 g/dL regardless of presence of clinical signs or symptoms) through Day 183.

Outcome measures

Measure	Ravulizumab/Ravulizumab n=97 Participants On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Eculizumab/Ravulizumab n=98 Participants Participants who were randomized to the eculizumab group in the Primary Evaluation Period received a weight-based loading dose of ravulizumab on Day 183 followed by weight-based maintenance doses of ravulizumab 2 weeks later and q8w until the end of study (up to 4 years).
Percentage Of Participants Who Achieved Transfusion Avoidance Through Day 183	87.6 percentage of participants Interval 81.08 to 94.18	82.7 percentage of participants Interval 75.16 to 90.15

SECONDARY outcome

Timeframe: Baseline through Day 183

Population: Full Analysis Set: All participants who received at least 1 dose of randomized treatment (ravulizumab or eculizumab).

Stabilized hemoglobin was defined as avoidance of a ≥2 g/dL decrease in hemoglobin level from Baseline in the absence of transfusion through Day 183.

Outcome measures

Measure	Ravulizumab/Ravulizumab n=97 Participants On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Eculizumab/Ravulizumab n=98 Participants Participants who were randomized to the eculizumab group in the Primary Evaluation Period received a weight-based loading dose of ravulizumab on Day 183 followed by weight-based maintenance doses of ravulizumab 2 weeks later and q8w until the end of study (up to 4 years).
Percentage Of Participants With Stabilized Hemoglobin Levels Through Day 183	76.3 percentage of participants Interval 67.82 to 84.75	75.5 percentage of participants Interval 67.0 to 84.02

SECONDARY outcome

Timeframe: Baseline through end of study (up to 4 years)

Population: Full Analysis Set: All participants who received at least 1 dose of randomized treatment (ravulizumab or eculizumab). Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

BTH was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia [hemoglobin <10 g/dL], major adverse vascular event [including thrombosis], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 times the ULN.

Outcome measures

Measure	Ravulizumab/Ravulizumab n=96 Participants On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Eculizumab/Ravulizumab n=95 Participants Participants who were randomized to the eculizumab group in the Primary Evaluation Period received a weight-based loading dose of ravulizumab on Day 183 followed by weight-based maintenance doses of ravulizumab 2 weeks later and q8w until the end of study (up to 4 years).
Number Of Participants With Breakthrough Hemolysis Through End of Study	9 number of participants Interval 4.38 to 17.05	6 number of participants Interval 2.35 to 13.24

SECONDARY outcome

Timeframe: Baseline, End of Study (up to 4 years)

Population: Full Analysis Set: All participants who received at least 1 dose of randomized treatment (ravulizumab or eculizumab). Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

FACIT-Fatigue score ranges from 0 to 52, with a higher score indicating less fatigue. Baseline was defined as the last non-missing assessment value prior to first study drug dose. Change in FACIT-Fatigue score from Baseline to Day 183 was analyzed using an MMRM with the fixed, categorical effects of treatment, the stratification randomization indicator of packed red blood cells transfusion history (yes/no within 12 months prior to Day 1), study visit, and study visit by treatment group interaction, as well as the continuous fixed covariate of Baseline FACIT-Fatigue score.

Outcome measures

Measure	Ravulizumab/Ravulizumab n=14 Participants On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Eculizumab/Ravulizumab n=13 Participants Participants who were randomized to the eculizumab group in the Primary Evaluation Period received a weight-based loading dose of ravulizumab on Day 183 followed by weight-based maintenance doses of ravulizumab 2 weeks later and q8w until the end of study (up to 4 years).
Change From Baseline To End of Study In FACIT-Fatigue Scores Through End of Study	-1.43 units on a scale Standard Deviation 5.694	0.00 units on a scale Standard Deviation 5.944

SECONDARY outcome

Timeframe: Baseline through end of study (up to 4 years)

Population: Full Analysis Set: All participants who received at least 1 dose of randomized treatment (ravulizumab or eculizumab). Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

Transfusion avoidance was defined as the percentage of participants who remained transfusion free and did not require a transfusion per protocol-specified guidelines (hemoglobin value of ≤9 g/dL with signs or symptoms of sufficient severity to warrant a transfusion, or a hemoglobin value of ≤7 g/dL regardless of presence of clinical signs or symptoms) through the end of study.

Outcome measures

Measure	Ravulizumab/Ravulizumab n=96 Participants On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Eculizumab/Ravulizumab n=95 Participants Participants who were randomized to the eculizumab group in the Primary Evaluation Period received a weight-based loading dose of ravulizumab on Day 183 followed by weight-based maintenance doses of ravulizumab 2 weeks later and q8w until the end of study (up to 4 years).
Percentage Of Participants Who Achieved Transfusion Avoidance Through End of Study	70.83 percentage of participants Interval 60.67 to 79.67	70.53 percentage of participants Interval 60.29 to 79.44

SECONDARY outcome

Timeframe: Baseline through end of study (up to 4 years)

Population: Full Analysis Set: All participants who received at least 1 dose of randomized treatment (ravulizumab or eculizumab). Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

Stabilized hemoglobin was defined as avoidance of a ≥2 g/dL decrease in hemoglobin level from Baseline in the absence of transfusion through end of study.

Outcome measures

Measure	Ravulizumab/Ravulizumab n=96 Participants On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Eculizumab/Ravulizumab n=95 Participants Participants who were randomized to the eculizumab group in the Primary Evaluation Period received a weight-based loading dose of ravulizumab on Day 183 followed by weight-based maintenance doses of ravulizumab 2 weeks later and q8w until the end of study (up to 4 years).
Percentage Of Participants With Stabilized Hemoglobin Levels Through End of Study	58.33 percentage of participants Interval 47.82 to 68.32	67.37 percentage of participants Interval 59.68 to 76.64

Adverse Events

Primary Evaluation Period (26 Weeks) Ravulizumab Treatment

Serious events: 4 serious events

Other events: 72 other events

Deaths: 0 deaths

Primary Evaluation Period (26 Weeks) Eculizumab Treatment

Serious events: 8 serious events

Other events: 85 other events

Deaths: 0 deaths

Extension Period (Ravulizumab To Ravulizumab)

Serious events: 26 serious events

Other events: 83 other events

Deaths: 0 deaths

Extension Period (Eculizumab to Ravulizumab)

Serious events: 33 serious events

Other events: 85 other events

Deaths: 3 deaths

Serious adverse events

Measure	Primary Evaluation Period (26 Weeks) Ravulizumab Treatment n=97 participants at risk On Day 1, participants received weight- based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127.	Primary Evaluation Period (26 Weeks) Eculizumab Treatment n=98 participants at risk Participants received 900 mg of eculizumab q2w for 26 weeks.	Extension Period (Ravulizumab To Ravulizumab) n=96 participants at risk After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Extension Period (Eculizumab to Ravulizumab) n=95 participants at risk After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.
Blood and lymphatic system disorders Haemolysis	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	2.0% 2/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	4.2% 4/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Cardiac disorders Palpitations	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Gastrointestinal disorders Colitis	1.0% 1/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
General disorders Hyperthermia	1.0% 1/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
General disorders Pyrexia	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	3.1% 3/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.2% 5/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Hepatobiliary disorders Cholelithiasis	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Influenza	1.0% 1/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	3.2% 3/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Lower respiratory tract infection	1.0% 1/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Pyelonephritis acute	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Nervous system disorders Epilepsy	1.0% 1/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Respiratory, thoracic and mediastinal disorders Respiratory failure	1.0% 1/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Blood and lymphatic system disorders Haemolytic anaemia	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	2.1% 2/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Blood and lymphatic system disorders Anaemia	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Blood and lymphatic system disorders Aplastic anaemia	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Blood and lymphatic system disorders Bone marrow failure	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Blood and lymphatic system disorders Breakthrough haemolysis	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Gastrointestinal disorders Enteritis	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Gastrointestinal disorders Pneumoperitoneum	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Gastrointestinal disorders Toothache	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Hepatobiliary disorders Bile duct stone	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Hepatobiliary disorders Biliary colic	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Hepatobiliary disorders Cholecystitis	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Hepatobiliary disorders Liver disorder	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations COVID-19	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Infection	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	2.1% 2/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Pneumonia	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Bacteraemia	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Escherichia sepsis	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Escherichia urinary tract infection	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Gastroenteritis	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Pharyngitis	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Pneumococcal infection	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Pneumonia bacterial	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Post procedural infection	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Postoperative wound infection	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Rhinovirus infection	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Septic shock	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Suspected COVID-19	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Urinary tract infection	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Injury, poisoning and procedural complications Ligament injury	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Injury, poisoning and procedural complications Road traffic accident	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Injury, poisoning and procedural complications Tibia fracture	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Injury, poisoning and procedural complications Lower limb fracture	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Injury, poisoning and procedural complications Transfusion reaction	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Nervous system disorders Cerebrospinal fluid retention	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Nervous system disorders Loss of consciousness	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Musculoskeletal and connective tissue disorders Dupuytren's contracture	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Musculoskeletal and connective tissue disorders Foot deformity	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Musculoskeletal and connective tissue disorders Intervertebral disc degeneration	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Musculoskeletal and connective tissue disorders Osteonecrosis	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Renal and urinary disorders Ureterolithiasis	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Renal and urinary disorders Urinary retention	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Investigations Liver function test increased	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Psychiatric disorders Depression	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Psychiatric disorders Major depression	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Psychiatric disorders Suicide attempt	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Skin and subcutaneous tissue disorders Dermal cyst	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Vascular disorders Deep vein thrombosis	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Endometrial cancer	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung cancer metastatic	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cancer metastatic	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Seborrhoeic keratosis	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive papillary breast carcinoma	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.1% 1/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.

Other adverse events

Measure	Primary Evaluation Period (26 Weeks) Ravulizumab Treatment n=97 participants at risk On Day 1, participants received weight- based doses of ravulizumab ranging from 2400 to 3000 mg. Thereafter, weight- based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127.	Primary Evaluation Period (26 Weeks) Eculizumab Treatment n=98 participants at risk Participants received 900 mg of eculizumab q2w for 26 weeks.	Extension Period (Ravulizumab To Ravulizumab) n=96 participants at risk After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.	Extension Period (Eculizumab to Ravulizumab) n=95 participants at risk After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 4 years.
Blood and lymphatic system disorders Anaemia	5.2% 5/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	3.1% 3/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	4.2% 4/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	7.4% 7/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Gastrointestinal disorders Abdominal pain	7.2% 7/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	9.2% 9/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	12.5% 12/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	11.6% 11/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Gastrointestinal disorders Constipation	6.2% 6/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.1% 5/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	3.1% 3/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.3% 5/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Gastrointestinal disorders Diarrhoea	9.3% 9/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	7.1% 7/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	15.6% 15/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	14.7% 14/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Gastrointestinal disorders Nausea	8.2% 8/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	9.2% 9/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	13.5% 13/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	16.8% 16/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Gastrointestinal disorders Vomiting	6.2% 6/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	4.1% 4/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	7.3% 7/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	4.2% 4/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
General disorders Chest pain	3.1% 3/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	9.2% 9/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.2% 5/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.3% 5/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
General disorders Fatigue	7.2% 7/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	6.1% 6/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	18.8% 18/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	20.0% 19/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
General disorders Influenza like illness	6.2% 6/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	8.2% 8/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	9.4% 9/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	9.5% 9/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
General disorders Pyrexia	9.3% 9/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	2.0% 2/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	15.6% 15/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	16.8% 16/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Nasopharyngitis	20.6% 20/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	20.4% 20/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	28.1% 27/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	22.1% 21/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Rhinitis	5.2% 5/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	4.1% 4/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	10.4% 10/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	7.4% 7/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Upper respiratory tract infection	19.6% 19/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	10.2% 10/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	25.0% 24/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	20.0% 19/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.1% 5/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Musculoskeletal and connective tissue disorders Pain in extremity	5.2% 5/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	4.1% 4/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	9.4% 9/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	11.6% 11/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Skin and subcutaneous tissue disorders Pruritus	1.0% 1/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.2% 5/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	4.2% 4/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Nervous system disorders Dizziness	3.1% 3/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	7.1% 7/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	8.3% 8/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	15.8% 15/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Nervous system disorders Headache	27.8% 27/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	17.3% 17/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	21.9% 21/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	22.1% 21/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Respiratory, thoracic and mediastinal disorders Cough	5.2% 5/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	10.2% 10/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	16.7% 16/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	12.6% 12/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	6.1% 6/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	8.3% 8/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	8.4% 8/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	4.1% 4/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	9.2% 9/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	7.3% 7/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	10.5% 10/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Gastrointestinal disorders Abdominal pain upper	2.1% 2/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	7.3% 7/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	8.4% 8/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Gastrointestinal disorders Dysphagia	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	6.2% 6/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.3% 5/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Urinary tract infection	1.0% 1/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	7.3% 7/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	8.4% 8/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Gastroenteritis	1.0% 1/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	7.3% 7/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	3.2% 3/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Influenza	1.0% 1/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.2% 5/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	4.2% 4/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Musculoskeletal and connective tissue disorders Back pain	4.1% 4/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	10.4% 10/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	13.7% 13/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Musculoskeletal and connective tissue disorders Arthralgia	5.2% 5/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	11.5% 11/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	7.4% 7/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Musculoskeletal and connective tissue disorders Myalgia	2.1% 2/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	3.1% 3/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	6.3% 6/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Cardiac disorders Palpitations	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.2% 5/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.3% 5/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Blood and lymphatic system disorders Neutropenia	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.2% 5/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	3.2% 3/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Ear and labyrinth disorders Ear pain	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.3% 5/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.2% 5/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	4.2% 4/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
General disorders Oedema peripheral	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.2% 5/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	4.2% 4/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
General disorders Asthenia	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.2% 5/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	2.1% 2/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Hepatobiliary disorders Cholelithiasis	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	2.1% 2/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.3% 5/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations COVID-19	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.2% 5/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	3.2% 3/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Respiratory tract infection	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	2.1% 2/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.3% 5/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Infection	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.3% 5/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Injury, poisoning and procedural complications Contusion	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	6.2% 6/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	2.1% 2/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.2% 5/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	2.1% 2/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Nervous system disorders Migraine	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	3.1% 3/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.3% 5/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Renal and urinary disorders Chromaturia	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	1.0% 1/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.3% 5/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	5.2% 5/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	2.1% 2/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.
Infections and infestations Viral infection	0.00% 0/97 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	0.00% 0/98 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	6.2% 6/96 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.	3.2% 3/95 • From Baseline (after first dose) to end of study (up to 4 years) Primary Evaluation Period (26 weeks)- Ravulizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for participants in the Ravulizumab-Treated Set. Eculizumab Treatment: data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Safety Set. Extension Period-data for All-Cause Mortality, Serious Adverse Events, and Other Adverse Events are for the participants in the Ravulizumab-Treated Set.

Additional Information

Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals Inc.

Phone: 855-752-2356

Email: clinicaltrials@alexion.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place